Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Nasal Spray for Epistaxis in HHT
NCT02106520Phase 3Terminated
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2014
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), epistaxis, sponsored by Hospices Civils de Lyon. Started Apr 2014; status: terminated.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)epistaxis
Beyond the preview
Go deeper on NCT02106520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106520.